Evertor 10mg tablet - Everolimus | Myapplepharma

Description

Evertor belongs to the class of anti-cancer drugs Evertor contains an active compound known as Everolimus which interferes with the development of cancer cell and the process is slowed down. Evertor tablets is not a curable medication, which helps to slow their spreading into the body.

Prescribed For

The drug Evertor is mainly indicated for the treatment of the following disease
• kidney carcinoma
• Breast carcinoma
• Brain carcinoma
Evertor is also used to treat in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism

Evertor is a prohibition of mTOR, links at peak compatibility to FK506 binding protein 12, through producing drug complex which prevents the productive of mTOR, the main ingredient which is used as everolimus. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, Finally causes cell growth arrest and apoptosis

Dosage regimen of Evertor

In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer: The prescribed dosage is 10mg should be taken as a single dose. In Brain or intracranial cancer: The prescribed dosage of Evertor as a single dose. is 4.5mg/m2 given orally In pediatric: The pediatric dosage of Evertor as a single dose in brain or intracranial tumor is 4.5mg/m2 should be given orally.

Drug-Drug interaction

Interaction of Evertor with strong inhibitor of CYP3A4, or P-gp, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus. Concomitant use of Evertor with strong CYP3A4 inducers will be increasing the disclosure of Everolimus. Interaction of Evertor with cyclosporine will increase the AUC level of Everolimus frequently.

Side Effects

• Nephrotoxicity
• Thrombocytopenia
• Hypersensitivity reactions
• Hyperlipemia
• Angioedema
• Lymphomas & other malignancy
• Male infertility

Overdosage

The over dosage of Everolimus is limited If overdosage occurs patient must be provided with supportive measures. And monitor evidence of toxicity in Everolimus overdosage

Missed Dose

If the patients missed the dose, patients must consult with the medical practitioner and follow the instructions given by them. Or missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION

EMAIL:


applepharmaceutical@gmail.com

PHONE:


91- 9987711567


Comments

Post a Comment

Popular posts from this blog

Cabozantinib (Cometriq, Cabometyx) tablet Online | Apple pharmaceuticals

DESCRIPTION Cabozantinib  which is a type of targeted therapy drug used to recover from medullary thyroid cancer and kidney cancer that has spread. Its label contains a black box warning of gastrointestinal perforations, fistulas, and hemorrhage. Cabozantinib is a prescription drug which is used under the supervision of doctors INDICATION Cabozantinib  is used for the treatment of metastatic medullary thyroid cancer and for the treatment of patients having advanced renal cell carcinoma (RCC) who have to get before anti-angiogenic therapy. MECHANISM Cabozantinib   is also called a tyrosine kinase inhibitor (targeted therapy drug). It works by prohibiting the signals inside cancer cells which made them grow and multiply. This may help to block or reduced the growth of cancer. It can also prohibit new blood vessels growing in cancer. Cancer cells require to make new blood vessels so they can develop and spread. DOSAGE MODIFICATION Avoid substitute  Caboz...
Read more

Everotas 5mg tablet - Everolimus | Myapplepharma

DESCRIPTION Everotas 5mg belongs to a class of anti-cancer drugs. Everotas 5mg contains an active compound known as Everolimus which interferes with the development of cancer cell and the process is slowed down. Everotas 5mg tablets is not a curable medication, which helps to slow their spreading into the body. PRESCRIBED FOR The drug Everotas 5mg is mainly used for the treatment of the following disease • kidney carcinoma • Breast carcinoma • Brain carcinoma Everotas 5mg is also used to treat in various advanced stage cancer in stomach, intestines or pancreas. CLINICAL PHARMACOLOGY OF EVEROTAS Everolimus is a prohibition of mTOR, links at peak compatibility to FK506 binding protein 12, through producing drug complex which prevents the productive of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis. Everotas also prohibits the express...
Read more